Caudatin inhibits human hepatoma cell growth and metastasis through modulation of the Wnt/β-catenin pathway

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2923-2928

  Luo, Yi ^a,b   Sun, Zhiguang ^a   Li, Youbin ^c   Liu, Lina ^a   Cai, Xueting ^c   Li, Zhenlin ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

catenin; Caudatin; Cell growth; Human hepatoma cells; Metastasis; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CAUDATIN; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; COX 2 GENE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; METASTASIS; MMP 2 GENE; MMP 9 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN SECRETION;

APOPTOSIS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSIDES; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; STEROIDS; WNT SIGNALING PATHWAY;

EID: 84892394499     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2749     Document Type: Article

References (24)

1. O'Brien K, Cokkinides V, Jemal A, et al: Cancer statistics for Hispanics, 2003. CA Cancer J Clin 53: 208-226, 2003.
2. Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
3. Bruix J, Raoul JL, Sherman M, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57: 821-829, 2012.
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Su M, Wu X, Chung HY, Li Y and Ye W: Antiproliferative activities of five Chinese medicinal herbs and active compounds in Elephantopus scaber. Nat Prod Commun 4: 1025-1030, 2009.
6. Chang C, Zhu Y, Tang X and Tao W: The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol Biol Rep 38: 163-169, 2011.
7. 2, L-glutamate, and kainate. J Neurosci Res 59: 259-264, 2000.
8. 4 in-vitro by cynandione A, a biacetophenone from Cynanchum wilfordii. J Pharm Pharmacol 52: 341-345, 2000.
9. Peng YR, Ding YF, Wei YJ, Shu B, Li YB and Liu XD: Caudatin-2,6-dideoxy- 3-O-methy-β-D-cymaropyranoside 1 induced apoptosis through caspase 3-dependent pathway in human hepatoma cell line SMMC-7721. Phytother Res 25: 631-637, 2011.
10. Zhang JF, Li YB, Li CL and Jiang JQ: Studies on chemical constituents in root tuber of Cynanchum auriculatum. Zhongguo Zhong Yao Za Zhi 31: 814-816, 2006 (In Chinese).
11. Pongracz JE and Stockley RA: Wnt signalling in lung development and diseases. Respir Res 7: 15, 2006.
12. MacDonald BT, Tamai K and He X: Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
13. Behari J: The Wnt/β-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol 4: 745-756, 2010.
14. El Wakil A and Lalli E: The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 332: 32-37, 2011.
15. Monga SP: Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 43: 1021-1029, 2011.
16. Xiong F, Leonov S, Howard AC, et al: Receptor for advanced glycation end products (RAGE) prevents endothelial cell membrane resealing and regulates F-actin remodeling in a β-catenin-dependent manner. J Biol Chem 286: 35061-35070, 2011.
17. Goodwin AM and D'Amore PA: Wnt signaling in the vasculature. Angiogenesis 5: 1-9, 2002.
18. Mei JM, Borchert GL, Donald SP and Phang JM: Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of β-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis 23: 2119-2122, 2002.
19. Arii S, Mise M, Harada T, et al: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24: 316-322, 1996.
20. Kamel L, Nessim I, Abd-el-Hady A, Ghali A and Ismail A: Assessment of the clinical significance of serum vascular endothelial growth factor and matrix metalloproteinase-9 in patients with hepatocellular carcinoma. J Egypt Soc Parasitol 35: 875-890, 2005.
21. Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050-6054, 2001.
22. Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P and Johnsen JI: Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 70: 266-276, 2010.
23. Tung JN, Chiang CC, Tsai YY, et al: CyclinD1 protein expressed in pterygia is associated with β-catenin protein localization. Mol Vis 16: 2733-2738, 2010.
24. Zhang JY, Tao LY, Liang YJ, et al: Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3β/β-catenin/c-Myc pathway. Cell Cycle 8: 2444-2450, 2009.